Journal of Jilin University(Medicine Edition) ›› 2020, Vol. 46 ›› Issue (6): 1324-1331.doi: 10.13481/j.1671-587x.20200634
• Review • Previous Articles
Research progress in diagnosis and treatment of non-alcoholic fatty liver disease combinated with type 2 diabetes mellitus
-
Received:2020-03-27Online:2020-11-28Published:2022-08-24
CLC Number:
- R587.1
Cite this article
share this article
| 1 | YOUNOSSI Z M， GOLABI P， DE AVILA L， et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes： a systematic review and meta-analysis［J］. J Hepatol， 2019， 71（4）： 793-801. |
| 2 | 中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南（2018年更新版）［J］. 中华肝胆病杂志， 2018， 26（3）： 195-203. |
| 3 | STEFAN N， HÄRING H U， CUSI K. Non-alcoholic fatty liver disease： causes， diagnosis， cardiometabolic consequences， and treatment strategies［J］. Lancet Diabetes Endocrinol， 2019， 7（4）： 313-324. |
| 4 | YOUNOSSI Z M， TAMPI R P， RACILA A， et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US［J］. Diabetes Care， 2020， 43（2）： 283-289. |
| 5 | DIEHL A M， DAY C. Cause， pathogenesis， and treatment of nonalcoholic steatohepatitis［J］. N Engl J Med， 2017， 377（21）： 2063-2072. |
| 6 | SBERNA A L， BOUILLET B， ROULAND A， et al. European Association for the Study of the Liver （EASL）， European Association for the Study of Diabetes （EASD） and European Association for the Study of Obesity （EASO） clinical practice recommendations for the management of non-alcoholic fatty liver disease： evaluation of their application in people with Type 2 diabetes［J］. Diabet Med， 2018， 35（3）： 368-375. |
| 7 | AMERICAN DIABETES ASSOCIATION. Comprehensive medical evaluation and assessment of comorbidities： Standards of medical care in diabetes-2020［J］.Diabetes Care， 2020， 43（）： S37-S47. |
| 8 | BRIL F， MCPHAUL M J， CAULFIELD M P， et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes［J］. Diabetes Care， 2020， 43（2）： 290-297. |
| 9 | CHALASANI N， YOUNOSSI Z， LAVINE J E， et al. The diagnosis and management of nonalcoholic fatty liver disease： Practice guidance from the American Association for the Study of Liver Diseases［J］. Hepatology， 2018， 67（1）： 328-357. |
| 10 | ORTIZ-LOPEZ C， LOMONACO R， ORSAK B， et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease （NAFLD）［J］. Diabetes Care， 2012， 35（4）： 873-878. |
| 11 | MATTHEW C. RIDDLE M， GEORGE B M， LAWRENCE B M， et al . Obesity management for the treatment of type 2 diabetes： Standards of Medical Care in Diabetes-2020［J］. Diabetes Care， 2020， 43（）： S89-S97. |
| 12 | BELL L N， WANG J X， MURALIDHARAN S， et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis： a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study［J］. Hepatology， 2012，56（4）： 1311-1318. |
| 13 | HARRISON S A， ALKHOURI N， DAVISON B A， et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis： a randomized， double-blind， placebo-controlled phase IIb study［J］. J Hepatol， 2020， 72（4）： 613-626. |
| 14 | IWASAKI T， YONEDA M， INAMORI M， et al. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus［J］. Hepatogastroenterology， 2011， 58（112）： 2103-2105. |
| 15 | JOY T R， MCKENZIE C A， TIRONA R G， et al. Sitagliptin in patients with non-alcoholic steatohepatitis： a randomized， placebo-controlled trial［J］. World J Gastroenterol， 2017， 23（1）： 141-150. |
| 16 | CUI J， PHILO L， NGUYEN P， et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease： a randomized controlled trial［J］. J Hepatol， 2016， 65（2）： 369-376. |
| 17 | CUSI K. Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes［J］. Diabetes Care， 2020， 43（2）： 275-279. |
| 18 | JOJIMA T， TOMOTSUNE T， IIJIMA T， et al. Empagliflozin （an SGLT2 inhibitor）， alone or in combination with linagliptin （a DPP-4 inhibitor）， prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes［J］. Diabetol Metab Syndr， 2016， 8：45. |
| 19 | NISHIMURA N， KITADE M， NOGUCHI R， et al. Ipragliflozin， a sodium-glucose cotransporter 2 inhibitor， ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats［J］. J Gastroenterol， 2016， 51（12）： 1141-1149. |
| 20 | KAHL S， GANCHEVA S， STRAßBURGER K， et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes： a randomized， double-blind， phase 4， placebo-controlled trial［J］. Diabetes Care， 2020， 43（2）： 298-305. |
| 21 | LATVA-RASKU A， HONKA M， KULLBERG J， et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity： a randomized， double-blind， placebo controlled study with 8-week treatment in type 2 diabetes patients［J］. Diabetes Care， 2019， 42（5）： 931-937. |
| 22 | ERIKSSON J W， LUNDKVIST P， JANSSON P A， et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes： a double-blind randomised placebo-controlled study［J］. Diabetologia， 2018， 61（9）： 1923-1934. |
| 23 | CUSI K， BRIL F， BARB D， et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes［J］. Diabetes Obes Metab， 2019， 21（4）： 812-821. |
| 24 | LEITER L A， FORST T， POLIDORI D， et al. Effect of canagliflozin on liver function tests in patients with type 2 diabetes［J］. Diabetes Metab， 2019， 42（1）： 25-32. |
| 25 | YU P， XU X， ZHANG J， et al. Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathway［J］. Int J Endocrinol， 2019， 2019： 1567095. |
| 26 | HAO T， CHEN H， WU S， et al. LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet［J］. Mol Med Rep， 2019， 20（1）： 701-708. |
| 27 | ARMSTRONG M J， HULL D， GUO K， et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis［J］. J Hepatol， 2016， 64（2）： 399-408. |
| 28 | ARMSTRONG M J， GAUNT P， AITHAL G P， et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis （LEAN）：a multicentre， double-blind， randomised， placebo-controlled phase 2 study［J］. Lancet， 2016， 387（10019）： 679-690. |
| 29 | PETIT J M， CERCUEIL J P， LOFFROY R， et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes： the lira-NAFLD study［J］. J Clin Endocrinol Metab， 2017， 102（2）： 407-415. |
| 30 | ARMSTRONG M J， HOULIHAN D D， ROWE I A. Pioglitazone， vitamin E， or placebo for nonalcoholic steatohepatitis［J］. N Engl J Med， 2010， 363（12）： 1185. |
| 31 | BRIL F， BIERNACKI D M， KALAVALAPALLI S， et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes： a randomized controlled trial［J］. Diabetes Care， 2019， 42（8）： 1481-1488. |
| 32 | ZANG S， CHEN J， SONG Y， et al. Haptoglobin genotype and vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis in China： a multicenter， randomized， placebo-controlled trial design［J］. Adv Ther， 2018， 35（2）： 218-231. |
| 33 | XU R F， ZHANG S S， TAO A Y， et al. Influence of vitamin E supplementation on glycaemic control： a meta-analysis of randomised controlled trials［J］. PLoS One， 2014， 9（4）： e95008. |
| 34 | WEI Z， YOSHIHARA E， HE N H， et al. Vitamin D switches BAF complexes to protect β cells［J］. Cell， 2018， 173（5）： 1135-1149.e15. |
| 35 | LEMIEUX P， WEISNAGEL S J， CARON A Z， et al. Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion： a randomised， placebo-controlled trial［J］. Eur J Endocrinol， 2019， 181（3）： 287-299. |
| 36 | GULSETH H L， WIUM C， ANGEL K， et al. Effects of vitamin D supplementation on insulin sensitivity and insulin secretion in subjects with type 2 diabetes and vitamin D deficiency： a randomized controlled trial［J］. Diabetes Care， 2017， 40（7）： 872-878. |
| 37 | MOUSA A， NADERPOOR N， DE COURTEN M P， et al. Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient， overweight or obese adults： a randomized placebo-controlled trial［J］. Am J Clin Nutr， 2017， 105（6）： 1372-1381. |
| 38 | BARCHETTA I， CIMINI F A， CAVALLO M G. Vitamin D supplementation and non-alcoholic fatty liver disease： present and future［J］. Nutrients， 2017， 9（9）：1015. |
| 39 | 姚诚子, 冯 巩,宇文思,等.非酒精性脂肪性肝病发生及进展的危险因素[J].临床肝胆病杂志,2020,36(2):433-436. |
| 40 | BRIL F， PORTILLO SANCHEZ P， LOMONACO R， et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis： post hoc analysis of a randomized trial［J］. J Clin Endocrinol Metab， 2017， 102（8）： 2950-2961. |
| 41 | ROGLANS N， SANGUINO E， PERIS C， et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats［J］. J Pharmacol Exp Ther， 2002， 302（1）： 232-239. |
| 42 | DONGIOVANNI P， PETTA S， MANNISTO V， et al. Statin use and non-alcoholic steatohepatitis in at risk individuals［J］. J Hepatol， 2015， 63（3）： 705-712. |
| 43 | NASCIMBENI F， ARON-WISNEWSKY J， PAIS R， et al. Statins， antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease［J］. BMJ Open Gastroenterol， 2016， 3（1）： e000075. |
| 44 | WU L， XIA M， DUAN Y， et al. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans［J］. Cell Death Dis， 2019， 10（6）： 468. |
| 45 | GUO T， WOO S L， GUO X， et al. Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity［J］. Sci Rep， 2016， 6： 22612. |
| 46 | YAN H M， XIA M F， WANG Y， et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease［J］. PLoS One， 2015， 10（8）： e0134172. |
| 47 | ARON-WISNEWSKY J， WARMBRUNN M V， NIEUWDORP M， et al. Nonalcoholic fatty liver disease： modulating gut microbiota to improve severity？［J］. Gastroenterology， 2020， 158（7）： 1881-1898. |
| 48 | JANG H R， PARK H J， KANG D， et al. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption［J］. Exp Mol Med， 2019， 51（8）： 1-14. |
| 49 | AHN S B， JUN D W， KANG B K， et al. Randomized， double-blind， placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease［J］. Sci Rep， 2019， 9（1）： 5688. |
| 50 | WANG Y， DILIDAXI D， WU Y， et al. Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice［J］. Biomed Pharmacother， 2020， 125： 109914. |
| 51 | KOUTNIKOVA H， GENSER B， MONTEIRO-SEPULVEDA M， et al. Impact of bacterial probiotics on obesity， diabetes and non-alcoholic fatty liver disease related variables： a systematic review and meta-analysis of randomised controlled trials［J］. BMJ Open， 2019， 9（3）： e017995. |
| [1] | Xin SHEN,Yang LIU,Hongyu CHEN,Jie ZHANG,Qingli CHENG,Guang YANG. Regulatory effect of high glucose on polarization of RAW264.7 macrophages via miR-125b in mice [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 847-857. |
| [2] | Yongxin ZHAI,Huaifeng TA,Yi ZHANG,Qijia SUN,Ming ZHANG,Shuqiang FENG,Ranwei LI. Effect of preoperative glycemic level on infection-related complications of diabetic patients after flexible ureteroscopic lithotripsy [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 766-772. |
| [3] | Junbo SUN,Da GAO,Yifei ZHAO,Hua XU,Fan QIU,Lu ZHAO. Improvement effect of paeonol on diabetic retinopathy in rats and its mechanism of regulating miR-802-5p expression [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 82-93. |
| [4] | Yu ZHU,Jingjing WANG,Fang WU. Expression of miR-150-5p in kidney tissue of diabetic nephropathy model mice and its effect on MPC5 mouse podocyte injury and mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 44-51. |
| [5] | ZHANG Yezhuo, YANG Yuefeng, YANG Yetong, ZHANG Ying, LIU Yajuan. Effects of poria cocos compound extract on blood glucose and lipid levels in rats with type 2 diabetes mellitus [J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 937-941. |
| [6] | WANG Lan, ZHU Guoshuang, SUN Long, WANG Xiaoqin. Improvement effect of Shenyuan Granule on vascular calcification in db/db diabetic nephropathy mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(03): 431-438. |
| [7] | LI Hongyan, WANG Lei, LIU Min, LIN Chongtao. Nifedipine-induced gingival enlargement in diabetic patient: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 399-403. |
| [8] | LIU Donghui, FU Wenliang, FU Xiumei, SONG Chengjun, CHEN Zhihong. Regulatory effect of sericin on liver insulin PI3K/Akt signaling pathway in rats of type 2 diabetes mellitus and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 228-232. |
| [9] | DU Xingxu, QIAO Zijing, YANG Shuo, XU Zhiying, YANG Bo, LI He, CHEN Jianguang, WANG Chunmei. Effect of Schisandra chinensis polysaccharide on serum inflammatory factors in T2DM rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 50-55. |
| [10] | SUN Yuanyuan, LIANG Li, WANG Xiaoye, XIAO Yan, GAO Ying. Improvement effect of dapagliflozin on liver function in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver diseaseand itsmechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 116-120. |
| [11] | SONG Na, SU Dongfeng, LIU Xiaoyan, GAO Yu, LIU Chang, LI Lihui. Protective effect of soy isoflavone on oxidative stress injury in perimenopause model rats with type 2 diabetes mellitus [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1310-1314. |
| [12] | WANG Ruibin, ZHAO Yanjie, SONG Qingkun, SHENG Minjia. Inhibitory effect of metformin on inflammatory responseof Kupffer cells of liver in diabetic mice and its improvement on phagocytic function [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 39-44. |
| [13] | JIA Zhanwei, LI Fengyi, HE Qiang, ZHANG Yubo, HAN Haixia, SHAN Chunguang. Influence of endoplasmic reticulum stress in degeneration of cochlear hair cells in type 2 diabetic mice [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 51-56. |
| [14] | WANG Haibing, DONG Zhijun, GUO Litao, SHI Jing, DONG Weili. Effects of Purendan Superfine Powder on retinal hemodynamics and expressions of cytokines in diabetic rats [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 57-62. |
| [15] | PAN Hong, WANG Yufeng, HUANG Haipeng, ZHANG Liying, ZHONG Zhen, MA Shiqi, DONG Li, WANG Hongfeng. Influence of Adjust Zang Dredge Meridian electroacupuncture in expression of GRP78 in sciatic nerve cells of rats with diabetic peripheral neuropathy and its neuroprotective effect [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1124-1130. |
|
||